The Food and Drug Administration says it granted Emergency Use Authorization for CytoSorbent’s (NASDAQ:CTSO) CytoSorb device to treat patients with confirmed Covid-19 admitted to the ICU with confirmed or imminent respiratory failure.
Based on bench performance testing and reported
clinical experience, the FDA concludes the CytoSorb device – also
referred to as an Extracorporeal Blood Purification device – may be
effective at treating certain patients with confirmed Covid-19 by
removing various pro-inflammatory cytokines from their blood.
The FDA believes the removal of pro-inflammatory
cytokines may ameliorate cytokine storm due to the overabundance of
pro-inflammatory cytokines and thus provide clinical benefit.
https://seekingalpha.com/news/3559968-cytosorbents-ebp-device-wins-emergency-ok-to-treat-covidminus-19-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.